key: cord-0258430-ezj2berk
authors: Shmeleva, Evgeniya V.; de Agüero, Mercedes Gomez; Wagner, Josef; Enright, Anton J.; Macpherson, Andrew J.; Ferguson, Brian J.; Smith, Geoffrey L.
title: Smallpox vaccination induces a substantial increase in commensal skin bacteria that promote pathology and enhance immunity
date: 2021-07-30
journal: bioRxiv
DOI: 10.1101/2021.07.30.454438
sha: 0abb59e32d8f55187035b7a29941f4c3e857abea
doc_id: 258430
cord_uid: ezj2berk

Interactions between pathogens, host microbiota and the immune system influence many physiological and pathological processes. In the 20th century, widespread dermal vaccination with vaccinia virus (VACV) led to the eradication of smallpox but how VACV interacts with the microbiota and whether this influences the efficacy of vaccination are largely unknown. Here we report that intradermal vaccination with VACV induces a large increase in the number of commensal bacteria in infected tissue, which enhance recruitment of inflammatory cells, promote tissue damage and increase immunity. Treatment of vaccinated specific-pathogen-free (SPF) mice with antibiotic, or infection of genetically-matched germ-free (GF) animals caused smaller lesions without alteration in virus titre. Tissue damage correlated with enhanced neutrophil and T cell infiltration and levels of pro-inflammatory tissue cytokines and chemokines. One month after vaccination, GF mice had reduced VACV-neutralising antibodies compared to SPF mice; while numbers of VACV-specific CD8+ T cells were equal in all groups of animals. Thus, skin microbiota may provide an adjuvant-like stimulus during vaccination with VACV. This observation has implications for dermal vaccination with live vaccines. Author Summary Smallpox was caused by variola virus and was eradicated by widespread dermal vaccination with vaccinia virus (VACV), a related orthopoxvirus of unknown origin. Eradication was declared in 1980 without an understanding of the immunological correlates of protection, or knowledge of the effect of smallpox vaccination on the local microbiota. Here we demonstrate that intradermal infection of mice with VACV induces a ∼1000-fold expansion of commensal skin bacteria that influence the recruitment of inflammatory cells into the infected tissue and enhance the size of the vaccination lesion. Antibiotic treatment reduced lesion size without changing virus titres. The bacterial expansion also contributes to the level of neutralizing antibodies at one month post vaccination, because genetically matched germ-free mice developed lower neutralizing antibodies than specific pathogen free controls. Thus, dermal infection by VACV enhanced bacterial growth and these bacteria promote pathology and enhance the antibody response. This finding has implication for dermal vaccination with live vaccines.

218 To analyse the local inflammatory environment further, we measured an array of cytokines and 219 chemokines in the ear tissue at d 5, 8 and 12 p.i. in control and antibiotic-treated mice. Consistent with 220 the smaller lesions and reduction in cellular infiltration, among 17 different inflammatory mediators 221 measured, there were reductions of IFNɣ, TNFα, CCL2, CCL4, CCL7, CXCL1 and CXCL10 levels in 222 the antibiotic-treated group compared to controls at d 8, and also in the amount of CCL4 and CCL7 at 223 d 12 p.i. (Fig 6A) . Similar differences were also evident when comparing infected GF mice with SPF 224 mice. Levels of IFNɣ, TNFα, CCL2, CCL7, CXCL1 and CXCL10 were considerably diminished in 225 the GF mice ( Fig 6B) . These data indicate that the presence of skin microbiota accelerates overall 226 immune cell recruitment and cytokine/chemokine production in VACV-infected skin.

Humoral adaptive immune response is impaired in the absence of microbiota 229 To assess the role of microbiota in the generation of VACV-specific adaptive immunity, we measured 230 VACV-specific CD8 + T cell numbers and anti-VACV neutralising antibodies in samples obtained from 231 SPF groups, with or without antibiotic treatment, and GF mice one month after vaccination. Absolute 232 numbers of splenic CD4 + and CD8 + T cells, as well as VACV-specific CD8 + cells, were similar in all 233 three groups of animals ( Fig 7A, B) . However, the levels of VACV neutralising antibodies were 234 significantly lower in GF animals than in either group of SPF animals ( Fig 7C) . Despite the reduced 235 antibody response in the vaccinated GF mice, all groups showed protection from disease upon 236 intranasal challenge with a lethal dose of VACV (Fig 7D-F) . Each SPF group showed a small (~10%) 237 transient weight loss after challenge before recovery. These data indicate that the GF mice have an 238 impaired capacity to generate neutralising antibody following i.d. vaccination with VACV, but that 239 this does not affect their capacity to develop protective immunity against re-challenge in this model. 240 These data do not distinguish between the deficiency of antibody-dependent immunity in GF animals 241 per se and the decline in humoral immune responses due to a lack of stimulatory signals from 242 microbiota. We attempted to address this by comparing vaccination of GF and S. aureus gnotobiotic 243 mice, which were generated by mono-colonisation of GF animals with S. aureus strain NCTC 8325 244 two weeks prior to the i.d. vaccination with VACV. Unfortunately, mice reconstituted with S. aureus, 245 differed from GF controls with lower body mass and reduced subcutaneous and visceral fat, possibly 246 suggest ongoing inflammation after colonisation with S. aureus. For these reasons, S. aureus colonised 247 animals proved unsuitable for comparison. (Figs 5, 6) . Notably, in the absence of microbiota, antibody-mediated immunity 263 is impaired while the antigen-specific CD8 + T cell response is preserved (Fig 7) . (Fig 1C and D) possibly slowing down due to nutrient limitations and, after 5 dpi, the activation 285 of the immune system and leukocyte infiltration (Fig 5, Fig 6) , which limits bacterial growth and 286 increases their death. 287 288 Although increased bacterial, but not viral, load correlated with enhanced lesion size, these increased 289 bacteria were not sufficient for lesion formation, because bacteria increased 1-5 d p.i., before lesions 290 appeared on d 6 (Figs 1C, D and 3A, B). Furthermore, GF mice still developed lesions, although these 291 were delayed and diminished (Fig 3B) . Lesion size was also reduced in GF animals following dermal 292 scarification of VACV into the mouse tail (42). VACV infection may disrupt skin integrity due to 293 VACV-induced cytopathic effect (43) or cell motility (44) 304 Bacterial invasion provides potent activators of innate immunity that promote cytokine/chemokine 305 production and immune cell recruitment (47). Consistent with this, larger lesions were associated with 306 more neutrophils and T cells (Fig 5B) , and increased tissue cytokines and chemokines (Fig 6) . 319 320 Bacterial lipopolysaccharides, flagellin, DNA and toxins are used as adjuvants to stimulate innate 321 immunity and vaccine immunogenicity, mainly via enhanced antibody production (17). Consistent 322 with that, the innate immune response to vaccination of GF mice was lower than for genetically-323 matched SFP animals (Fig 6B) , and whereas VACV-specific CD8 + T cell memory did not depend on 324 microbiota, the humoral immune response was impaired in GF mice compared with SPF animals (Fig   325 7A-C) . Nonetheless, no reduction of anti-VACV antibodies in antibiotic-treated SPF animals was seen 326 (Fig 7C) , despite reduced cytokine/chemokine levels. This maybe because antibiotic treatment does 327 not eliminate bacteria, but limits their growth and spread. Others also reported reduced antibody 328 responses in both GF and antibiotic-treated animals (55, 56). However, these studies used animals 329 pretreated with antibiotic per os to induce alterations in the gut microbiome, while we administrated 330 antibiotics i.p. only from 1 d after infection by VACV. Previous studies suggested that the influence 331 of microbiota on T-cell memory may depend on the inoculation route or pathogen (55). Notably, the 332 induction of CD8 + T cell memory following i.d. vaccination with VACV is microbiota-independent 333 and not perturbed by the presence of bacteria in the skin, gut or elsewhere (Fig 7) . 334 335 Although VACV-specific memory CD8 + T cells may have functional differences in the absence of 336 microbiota (57), and despite reduced titres of VACV-specific neutralising antibodies, GF animals were 337 protected as well as SPF mice from i.n. challenge with VACV one month (Fig 7D-F) . SPF mice that 338 had been treated with antibiotic were also protected as well as control mice at 3 months after 

13 d after VACV infection 174 to suppress bacterial growth. C57BL/6 specific-pathogen-free (SPF) mice were infected i.d. with 175 VACV, and one group received antibiotic treatment (SPF, AB-group), while another received 176 phosphate-buffered saline (SPF, NoAB-group)

To confirm that this effect was due to the presence of 180 bacteria, rather than a non-specific consequence of antibiotic treatment, genetically-matched germ-free 181 (GF) mice were infected i.d. with VACV strain WR. These mice showed delayed lesion formation and 182 had a three-fold reduction

Topical administration of antibiotic creams on the infected ears also resulted in a reduction of lesion 185 size following VACV infection (S5 Fig). However, it was not possible to control the dose administered 186 because the animals tend to groom themselves and each other, leading to ingestion of the applied 187 creams. Antibiotic treatment can influence antiviral immunity when administered orally (26) and so to 188 minimise the influence on gut microbiota, the antibiotic was administered i

To avoid changes in microbiota prior to infection, antibiotic treatment was only started from d 1 p.i

Throughout ceftriaxone treatment, the health status of animals and their leukocyte composition in 191 peripheral blood, spleen and bone marrow were unaltered

193 Next the virus titres in infected tissue with or without antibiotic treatment were determined. Notably, 194 despite considerable differences in lesion size, the viral titres in

This indicated that: i) antibiotic treatment has no impact on virus replication, and ii) lesion size

Histological examination of infected lesions showed that necrosis of the ear tissue in the NoAB-group 199 of animals was substantially greater than in the AB-group (Fig 4A). A striking difference in histological 200 changes after VACV infection was also observed when comparing GF and SPF mice: ears of the GF 201 animals had significantly reduced cell infiltration and only very mild tissue necrosis

Collectively, these observations indicate that skin microbiota promote lesion development after VACV 203 infection and the smaller lesion sizes and lack of pathological tissue changes in GF and antibioticsharp increase of Ly6C + inflammatory monocytes on d 5, followed by large leukocyte infiltration at 211 d 7. Notably, the antibiotic-treated group showed a substantial reduction in the recruitment of multiple 212 subpopulations of myeloid and lymphoid cells at d 7 p.i. (Fig 5A). By d 12 p.i., several subpopulations 213 of leukocytes had declined

During infection there was a notable positive correlation between the lesion size and the numbers of 215 infiltrating neutrophils or TCRαβ T cells and this correlation did not hold for any other cell type

392 monoclonal antibodies (mAbs) were added to the cell suspension (S2 Table). The following mAbs 393 were included in the myeloid panel: anti-CD45

After final washing steps, cells were resuspended in PBS containing 4% 396 paraformaldehyde (PFA) and were analysed on a BD LSRFortessa (BD Biosciences)

Subpopulations 401 of splenic T cells were determined by staining with mAbs to CD45, CD3, CD8, CD4 and MHC 402 dextramer H-2Kb/TSYKFESV (S2 Table). an OMNI Tissue Homogeniser with plastic hard-tissue probes (OMNI International

Samples were stored at -80 ºC until use. After thawing, 300 µl of 438 homogenates were transferred to PowerBead tubes (Part of DNeasy UltraClean Microbial Kit, Qiagen, 439 Cat #12224-250) and 50 µl of SL solution

Cat 440 #12224-250) was added. The samples then underwent mechanical disruption by rapid agitation with 441 beads using a Fastprep 24-5G bead beater

) was used for the bacterial 16S library preparation 455 according to the manufacturer's instructions with the exception that 150 ng of material was used for 456 amplification with 11 and 22 PCR cycles for the first and

Kapa Pure beads (KappaBiosystems, Cat # KK8002, Roche) were applied for purification and size 458 selection of DNA with a volumetric ratio of 0.6X-0.8X. The final library was assessed by

ScreenTape assay (Tapestation Agilent

) for quality and 460 fragment size, then quantified by Qubit dsDNA High Sensitivity Assay kit (Invitrogen, Thermo Fisher 461 Scientific, Cat. # Q32854) and pooled to 10 nM. The final pool was quantified by qPCR with Kapa

Next generation sequencing was performed by paired-464 end sequencing of the V4 region using MiSeq Reagent Kit version 3, 600-cycle format (Illumina). clusters were identified by specifying the

The heatmaps show 50 families from the family taxon datasets, 61 genera from the genus taxon 474 datasets, and 72 species from the species taxon datasets

For the visualisation of microbial compositional differences 477 between the different sample groups/timepoints we plotted the microbial variances using a multivariate 478 method called Principal Component Analysis (PCA) for the family, genus, and species taxon level

Comparison between two groups of animals were 485 done by Mann-Whitney U-test. The two-way repeated measures

Bioinformatics Institute and will be released upon publication of this article. Accession number 492 PRJEB39345; Study: PRJEB39345 ena-STUDY-Department of

DC & MФ: dendritic cells and macrophages; ; Eosin: 505 eosinophils; Mon: monocytes; Neutr: neutrophils. Medians are shown. (B) Absolute numbers of 506 neutrophils infiltrating ear tissues at different times p.i. Mock: mock-control, 5 d post intradermal injection 507 of PBS (n=3-5 per time point). Medians are shown. (C) Bacterial colonies grown from homogenised ear 508 tissues and their 10-fold serial dilutions seeded on

Next generation 515 sequencing was performed for DNA samples extracted from tissue. (A) Principal Component Analysis clustering. Bacterial genera with a minimum abundance of 1% in at least five samples was 520 used for creation of the heat map. Five clusters are colour-coded with red, blue, green, violet and 521 orange

Fig 3. Skin microbiota promote lesion development after VACV infection

Specific pathogen free (SPF) or germ-free (GF) mice (n=5-15 per group) were injected intradermally with 525 10 4 PFU of VACV. SPF, AB animals received antibiotic i.p. from 1 d p.i.; SPF, NoAB animals received 526 i.p. injections with PBS. (A-B) Ear lesion sizes of AB and NoAB-groups (A) or GF or SPF mice (B). Means 527 and SEM are shown. Statistical analysis by two-way RM ANOVA test

NS -non-significant by Mann-Whitney test. Experiments (except for those 529 with GF mice) were performed at least twice and representative data from one experiment are shown

Group SPF NoAB received i.p. injections with PBS. (A) Images of haematoxylin and eosin

Skin microbiota advance immune cell recruitment into VACV infected tissue

From d 1 p.i. onwards, one group 541 (AB) received antibiotic (ceftriaxone) i.p. daily. The second group (NoAB) received PBS i.p. (A) 542 Numbers of myeloid and lymphoid cell of subpopulations were measured in ear tissues at 2, 5, 7 and 543 12 d p.i. (n=5 per group per time point)

Box 545 plots are shown

Spearman correlation analysis of lesion sizes versus numbers of neutrophils, Ly6C+monocytes, TCRγδ 547 T cells or TCRαβ (TCRγδ -) T cells recruited to site of infection. The experiment was performed twice

per group per time point) were injected i.d. with 10 4 PFU of VACV. SPF, AB-552 group received antibiotic (ceftriaxone) i.p. daily from 1 d p.i.; SPF, NoAB group received i.p. injections 553 with PBS. (A) Tissue levels of cytokines and chemokines were measured by multiplex assay (Luminex)

Means are shown. The 555 experiment was performed twice and data from one representative experiment are shown. (B) Tissue levels 556 of cytokines and chemokines in GF and SPF groups at d 10 p.i

Graphs show results two independent experiments

AB-group received i.p. 563 antibiotic treatment for 10 d from 1 d p.i. SPF, NoAB group received i.p. injections with PBS. Spleens and 564 serum samples were obtained at 34 d p.i. (A) Absolute number of splenic CD8 + and CD4 + T cells. Bars 565 represent means. (B) Absolute number of VACV-specific splenic CD8 + T cells

All experiments (except with GF mice) were performed once. (D-F): GF and SPF groups of mice (n=5 per group) were vaccinated ("vac") i.d. in 570 both ears with 10 4 PFU of VACV WR per ear

CD11c -CD45 + Siglec-F -Ly6G + ) extracted from 579 ear tissues at 9 d p.i. Red -signal from surface staining with mix of antibodies, blue -DAPI. Bars = 5 µm

Skin microbiome change after i.d. infection with VACV (Family)

Ear tissues were collected from SPF mice before (intact) and at 2, 5, 8 and 12 d p.i. with 10 4 PFU of VACV 583 WR and at d 8 post injection of PBS (mock), n = 15 per group per time point. Next generation sequencing 584 was performed on DNA extracted from the ear tissues. (A) Heatmap of bacterial families with hierarchical of the heat map

Skin microbiome change after i.d. infection with VACV (Species)

Next generation sequencing 594 was performed on DNA extracted from the ear tissues. (A) Results of Principal Component Analysis (PCA) of 0.1%. Ellipses represent a 40% confidence interval around the cluster centroid. (B) Relative 597 abundance of most prevalent taxa of ear tissue bacterial species. (C) Heatmap of bacterial species with 598 hierarchical clustering. Bacterial species with a minimum abundance of 1% in at least five samples was 599 used for creation of the heat map

Group AB were injected i.p. with antibiotic ceftriaxone daily from d 1 to 11 p.i. Group NoAB received i

Groups of C57BL/6 SPF mice (n=3-5 per group) were injected i.d. with 10 4 PFU of VACV strain WR. The 610 first group received topical administration with 3% tetracycline cream on

The second group received topical administration with 4% erythromycin cream on infected ears daily 612 from d 5 to 21 p.i. Group NoAB received topical application of neat vaseline. Data show the mean lesion 613 size +/-SEM

C57BL/6 SPF mice received i.p. injections with antibiotic (ceftriaxone) or PBS for 10 d, then numbers of 618 different subpopulations of myeloid and lymphoid cells were measured in blood (A), spleen (B) and bone 619 marrow (C) (n=5 per group). DC & MФ, dendritic cells and macrophages

AB-group received i.p. 626 antibiotic treatment for 10 d from 1 d p.i. SPF, NoAB group received i.p. injections with PBS. Spleens and 627 serum samples were obtained at 3.5 months p.i. (A) Absolute number of splenic CD8 +

Bars represent means. (B) Absolute number of VACV-specific splenic CD8 + T cells. Bars represent means

At 632 3.5 months p.i. groups were challenged i.n. with 10 7 PFU of VACV WR. Data represent the weight of each 633 mouse compared to the weight of the same animal before challenge

Gating strategy for flow cytometry of myeloid lineage cells

Cells were gated on their ability to scatter light. Doublets were excluded using a FSC-A versus FSC-H plot

The myeloid gate included CD45 + Zombie dye -CD3 -CD5 -CD19 -NK1.1 -cells. Further myeloid cell 640 subpopulations were classified as follows: Eosinophils: CD45 + CD3 -CD5 -CD19 -NK1.1 -CD11c -Siglec-F +

641 DC and MФ (dendritic cells and macrophages): CD45 + CD3 -CD5 -CD19 -NK1.1 -Siglec-F -CD11c +

642 Neutrophils: CD45 + CD3 -CD5 -CD19 -NK1.1 -CD11c -Siglec-F -Ly6G + ; Ly6C + Mon (inflammatory 643 monocytes): CD45 + CD3 -CD5 -CD19 -NK1.1 -CD11c -Siglec-F -Ly6G -CD11b + Ly6C +

Ly6C -Mon 644 (residential monocytes): CD45 + CD3 -CD5 -CD19 -NK1.1 -CD11c -Siglec-F -Ly6G -CD11b + Ly6C

646 S9 Fig. Gating strategy for flow cytometry of lymphoid lineage cells

Cells were gated on their ability to scatter light. Doublets were excluded using a FSC-A versus FSC-H plot

hemopoietic cells were gated as CD45 + Zombie dye -cells. Further lymphoid subpopulations were 650 classified as follows: NK cells: CD45 + CD3 -NK1

TCRɣẟ T cells: CD45 + CD3 + NK1.1 -TCRɣẟ +

CD4 T 651 cells: CD45 + CD3 + NK1.1 -TCRɣẟ -CD8 -CD4 +

CD8 T cells: CD45 + CD3 + NK1.1 -TCRɣẟ -CD4 -CD8 + . of ear pinnae with 10 4 PFU of VACV WR

Doublets were excluded using a FSC-A versus FSC-H plot. T 656 cells were classified as CD45 + Zombie dye -CD3 + cells and then divided into CD8 + and CD4 + T subsets and 657 with further gating of VACV-specific CD8 + T lymphocytes

Monoclonal antibodies and dyes used for staining cells prior to analysis by flow cytometry

Smallpox and its eradication

Complications of smallpox vaccination, 1968. 669 National surveillance in the United States

Smallpox vaccines: targets of protective immunity

Vaccinia virus immune evasion: mechanisms, virulence and immunogenicity

Modulating vaccinia virus immunomodulators to 675 improve immunological memory

Secondary bacterial infections associated with influenza 677 pandemics

Skin microbiota: a source of disease or defence? Br J

Skin microbiota-host interactions

What is your diagnosis? Journal of Avian Medicine and 683 Surgery

A case of facial cellulitis and necrotizing 685 lymphadenitis due to cowpox virus infection

Pathogenesis of fulminant 687 monkeypox with bacterial sepsis after experimental infection with West African monkeypox virus in 688 a cynomolgus monkey

Control of adaptive immunity by the innate immune system

Innate control of adaptive immunity: beyond the three-signal paradigm

Targeting the innate immune response with improved 695 vaccine adjuvants

Sustained antigen 697 availability during germinal center initiation enhances antibody responses to vaccination

Vaccine adjuvants: putting innate immunity to work

Reading PC, Smith GL. A kinetic analysis of immune mediators in the lungs of mice infected 704 with vaccinia virus and comparison with intradermal infection

Increased attenuation but decreased 708 immunogenicity by deletion of multiple vaccinia virus immunomodulators

Dermal infection with vaccinia virus reveals roles for 711 virus proteins not seen using other inoculation routes

Mouse microbiota models: comparing germ-free mice 722 and antibiotics treatment as tools for modifying gut bacteria

Gut microbiome and 726 aging: physiological and mechanistic insights

Role of the microbiota in immunity and inflammation

The commensal microbiota and viral infection: a 730 comprehensive review

Dual role of commensal bacteria in viral infections

Do the microbiota influence vaccines and protective immunity to pathogens? 734 issues of sovereignty, federalism, and points-testing in the prokaryotic and eukaryotic spaces of the 735 host-microbial superorganism

Epithelial antimicrobial defence of the skin and intestine

Dialogue between skin microbiota and immunity

Wound 741 healing and expression of antimicrobial peptides/polypeptides in human keratinocytes, a consequence 742 of common growth factors

Sebum free fatty acids 744 enhance the innate immune defense of human sebocytes by upregulating beta-defensin-2 expression

Inhibition of HeLa cell protein synthesis by the vaccinia virion

Secondary bacterial infections complicating skin lesions

Rapid cell division of Staphylococcus aureus 754 during colonization of the human nose

Staphylococcus aureus infection dynamics

Microbiota is 758 an essential element for mice to initiate a protective immunity against vaccinia virus

Studies on the mechanisms of vaccina virus 761 cytopathic effects. I. Inhibition of protein synthesis in infected cells is associated with virus-induced 762 RNA synthesis

Virus-induced cell motility

Steroid hormone synthesis by a vaccinia enzyme: a new type of virus 765 virulence factor

Steroid hormone synthesis by vaccinia virus suppresses 767 the inflammatory response to infection

Multi-receptor detection of individual bacterial products by the innate 769 immune system

Mechanisms of bacterial pathogenicity

The price of immunity

Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure

Clinical features of patients infected 777 with 2019 novel coronavirus in Wuhan

Longitudinal analyses 779 reveal immunological misfiring in severe COVID-19

Heightened Innate Immune Responses 781 in the Respiratory Tract of COVID-19 Patients

Neutrophilic 783 inflammation in the respiratory mucosa predisposes to RSV infection

Microbiota 785 regulates immune defense against respiratory tract influenza A virus infection

The intestinal flora is required to support 788 antibody responses to systemic immunization in infant and germ free mice

Gastrointestinal microbiome dysbiosis in infant mice 791 alters peripheral CD8(+) T cell receptor signaling

Enhanced efficacy of vaccination with vaccinia virus 793 in old vs. young mice

mixOmics: an R package for 'omics feature 795 selection and multiple data integration